Literature DB >> 16985913

Rising PSA during Testosterone Replacement Therapy.

John Gore, Jacob Rajfer.   

Abstract

Although testosterone replacement therapy (TRT) is indicated for the management of symptomatic hypogonadism, there is still controversy over whether TRT should be administered to middle-aged men for the clinical manifestations of andropause, regardless of whether the serum testosterone levels are depressed or not. Side effects of TRT may include fluid retention, gynecomastia, polycythemia, and exacerbation of existing prostate cancer. As a result, patients on TRT require meticulous surveillance including regular digital rectal examination and serum prostate-specific antigen (PSA) testing. Herein, we present the case of a middle-aged man with andropause and a rising PSA on TRT.

Entities:  

Year:  2004        PMID: 16985913      PMCID: PMC1472885     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  5 in total

Review 1.  Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

Authors:  Shalender Bhasin; Atam B Singh; Ricky Phong Mac; Ballentine Carter; Martin I Lee; Glenn R Cunningham
Journal:  J Androl       Date:  2003 May-Jun

Review 2.  Risks of testosterone-replacement therapy and recommendations for monitoring.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

3.  Treatment of androgen deficiency in the aging male.

Authors: 
Journal:  Fertil Steril       Date:  2004-05       Impact factor: 7.329

4.  Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

5.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

  5 in total
  2 in total

1.  Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.

Authors:  Alexander W Pastuszak; Amy M Pearlman; Win Shun Lai; Guilherme Godoy; Kumaran Sathyamoorthy; Joceline S Liu; Brian J Miles; Larry I Lipshultz; Mohit Khera
Journal:  J Urol       Date:  2013-02-08       Impact factor: 7.450

2.  MR-10 Enhances Men's Health by Improving Endogenous Male Sex Hormone Generation.

Authors:  Yoo-Hun Noh
Journal:  J Med Food       Date:  2018-09-04       Impact factor: 2.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.